GNPX News and Press, Genprex Inc. From 10/07/19

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Ge...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. A recently published...

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers.” To hear the NetworkNe...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Pote...

NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full ...

NetworkNewsWire Editorial Coverage : Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.’s (NASDAQ: GNPX) ( GNPX Profile ) TUSC2 prevented tumor growth against triple-negative breast c...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company's webcast presentation. The presentat...

Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, today announced that it will present at the Singular Research Midwestern Values Conference on September 19, 2019 via webcast. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the compan...

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth ...

A direct target of miR-138, TUSC2 mimics miR-138 knockdown Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex&#x...